Through drug-anchored genetic and chemical screens, biochemical analysis, and therapeutic studies, we found that signaling feedback via the EGFR pathway served as the dominant mechanism for the intrinsic resistance of CRC cells to KRASG12D inhibitor therapy. This evidence concerns the gene EGFR and colorectal carcinoma.